



## Rapamune® (sirolimus) – First-time generic

- On January 30, 2019, VistaPharm launched a generic version of Pfizer's [Rapamune \(sirolimus\)](#) oral solution.
- Rapamune is approved for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants and for the treatment of patients with lymphangioleiomyomatosis.
- Sirolimus is also available generically as an oral [tablet](#) that is approved for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants.
- Rapamune carries a boxed warning for immunosuppression and use is not recommended in liver or lung transplant patients.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.